Atrium Therapeutics, Inc. (RNA) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Atrium Therapeutics, Inc. $11.80, price $8.33, upside +41.7%, quality 51 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Atrium Therapeutics, Inc. Common Stock for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Sep 23, 2026.
How to read this chart
7‑month range $8.33 – $16.54 · fair‑value band $7.79 – $14.75 · the $8.33 price screens below the $11.80 fair value. As of Sep 23, 2026.
Follow Atrium Therapeutics, Inc. Common Stock in your weekly email
Every Wednesday you see whether Atrium Therapeutics, Inc. Common Stock is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies.
Show more
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. The company was incorporated in 2025 and is headquartered in San Diego, California.
Stock analysis
Atrium Therapeutics, Inc. Common Stock (RNA) currently trades at $8.33, while our model-based Fair Value estimate is $11.80, implying the stock looks roughly 29.4% undervalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.
Scenario range: $7.79 (bear) to $14.75 (bull), the price of $8.33 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 51/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Atrium Therapeutics, Inc. Common Stock reported revenue of $18.6M in FY2025 versus $9.3M in FY2021, a compound +18.9%/yr. Reported net income was −$76.7M in FY2025.
Key figures
Market cap $217M · P/S ratio 5.90 · EPS (TTM) $−5.02 · Net margin −160% · Return on equity −44.0% · Return on assets (EBIT) −29.0% · Operating margin −88.0% · Revenue (TTM) $36.7M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (low confidence).
What moves the price
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at 42%, RNA screens cheaper than that median.
Fair Value models
Bear $7.79Fair Value $11.80Bull $14.75
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.36/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+70.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+26.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+22.4%
Start year 2020 (pandemic)
Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.6%
’11
’12
’13
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−652.4% (2020) → −412.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Atrium Therapeutics, Inc. Common Stock with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 649 stocks
Beats the industry median on 5/8 measures
Overall it ranks above its industry peers.
Valuation
Quality Score49 · Above median
Fair Value upside+42% · Top 25%
Profitability
Net margin (TTM)−160% · Bottom 25%
Operating margin (TTM)−88% · Bottom 25%
Growth and dividend
Revenue growth11% · Above median
Balance sheet
Debt / equity0.01× · Below median
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Atrium Therapeutics, Inc. Common Stock Fair Value". https://www.fairvalue-calculator.com/stock/RNA
Frequently asked questions
Is Atrium Therapeutics, Inc. (RNA) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of $11.80 versus a price of $8.33, about +42% upside (undervalued).
What is the fair value of RNA?
Our model-based fair value for Atrium Therapeutics, Inc. Common Stock is $11.80 (as of Sep 23, 2026), built from audited fundamentals. The current price: $8.33.
What is the quality score of RNA?
Atrium Therapeutics, Inc. Common Stock has a Quality Score of 51/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Atrium Therapeutics, Inc. (RNA)?
Our model-based price target is the fair value of $11.80 (as of Sep 23, 2026) from 1 valuation models. Cautious scenario $7.79, optimistic scenario $14.75. It is a calculation from audited fundamentals, not an analyst target.
What is the Atrium Therapeutics, Inc. Common Stock stock forecast for 2026?
Our models put fair value at $11.80, about +42% upside versus a price of $8.33 (undervalued). Cautious scenario $7.79, optimistic scenario $14.75. The calculation is refreshed regularly with new filings.
What is the revenue of Atrium Therapeutics, Inc. (RNA)?
Atrium Therapeutics, Inc. Common Stock reported trailing-twelve-month revenue of about $36.7M (latest available figure, as of Sep 23, 2026).
What is the intrinsic value of Atrium Therapeutics, Inc. (RNA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Atrium Therapeutics, Inc. Common Stock it is $11.80 per share (as of Sep 23, 2026), against a price of $8.33. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Atrium Therapeutics, Inc. Common Stock stock overvalued or undervalued in 2026?
As of Sep 23, 2026, RNA trades below its calculated fair value: price $8.33, fair value $11.80, a gap of about +42% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of RNA?
No. The price is what the market pays today ($8.33); the fair value is what the company's own numbers justify ($11.80). For Atrium Therapeutics, Inc. Common Stock the two are $3.47 per share apart. That gap is exactly why we show both numbers side by side.
How much is Atrium Therapeutics, Inc. Common Stock worth?
The market values Atrium Therapeutics, Inc. Common Stock at about $217M (market capitalisation, as of Sep 23, 2026). Per share that is $8.33; our models calculate a fair value of $11.80 per share.
What do the bullish and bearish scenarios say about RNA?
Our models span a range for Atrium Therapeutics, Inc. Common Stock: cautious scenario $7.79, base $11.80, optimistic $14.75 per share (as of Sep 23, 2026, price $8.33). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Atrium Therapeutics, Inc. (RNA)?
Balance-sheet figures for Atrium Therapeutics, Inc. Common Stock (as of Sep 23, 2026): return on equity −44.0%, debt of 0.01 per unit of equity. They feed the Quality Score of 51/100, which measures business quality independently of the share price.
Which stocks are comparable to Atrium Therapeutics, Inc. Common Stock?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Atrium Therapeutics, Inc. Common Stock stock attractive at the current price?
The data as of Sep 23, 2026: price $8.33, calculated fair value $11.80 (+42%), Quality Score 51/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of RNA calculated?
We run Atrium Therapeutics, Inc. Common Stock through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $11.80, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Atrium Therapeutics, Inc. Common Stock currently trades 42 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Atrium Therapeutics, Inc. (RNA)?
The closing price on Sep 23, 2026 was $8.33. Our model-based fair value is $11.80, about +42% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Atrium Therapeutics, Inc. Common Stock right now?
The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (51/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range ($7.79 to $14.75) leaves room in how you read the outcome.
Key figures of Atrium Therapeutics, Inc. Common Stock
How large is the market capitalisation of Atrium Therapeutics, Inc. (RNA)?
The market capitalisation of Atrium Therapeutics, Inc. Common Stock is $217M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Atrium Therapeutics, Inc. (RNA)?
The price-to-sales ratio of Atrium Therapeutics, Inc. Common Stock is 5.90 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Atrium Therapeutics, Inc. (RNA)?
Earnings per share at Atrium Therapeutics, Inc. Common Stock are $−5.02. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Atrium Therapeutics, Inc. (RNA)?
The net margin of Atrium Therapeutics, Inc. Common Stock is −160% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Atrium Therapeutics, Inc. (RNA)?
The return on equity (ROE) of Atrium Therapeutics, Inc. Common Stock is −44.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Atrium Therapeutics, Inc. (RNA)?
On an EBIT basis the return on assets of Atrium Therapeutics, Inc. Common Stock is −29.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Atrium Therapeutics, Inc. (RNA)?
The operating margin of Atrium Therapeutics, Inc. Common Stock is −88.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Atrium Therapeutics, Inc. (RNA)?
Revenue at Atrium Therapeutics, Inc. Common Stock is growing +11.5% versus a year earlier (3y avg +26.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Atrium Therapeutics, Inc. (RNA) generate?
The free cash flow of Atrium Therapeutics, Inc. Common Stock is −$42.6M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Atrium Therapeutics, Inc. (RNA) hold?
Atrium Therapeutics, Inc. Common Stock holds more cash than debt, $266M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Atrium Therapeutics, Inc. Common Stock in the live analysis
One click puts Atrium Therapeutics, Inc. Common Stock on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 23, 2026